Skip to content
    AME
    Earnings call· Mar 2025(Q1 FY25)

    AMETEK INC/ Q1 FY25 earnings call AME

    May 1, 2025 Source

    Executive summary

    AMETEK Q1 FY25 — Strong Start with Robust Margins and Tariff Mitigation

    AMETEK delivered a strong Q1 FY25, marked by robust margin expansion and solid order growth, particularly in its EMG segment. The company is actively navigating increased trade policy uncertainty, especially regarding China tariffs, through comprehensive mitigation strategies and leveraging its diversified portfolio and global footprint. Management remains confident in its full-year outlook, emphasizing strategic investments and opportunistic capital deployment.

    Highlights

    5

    • Operating margins expanded by 60 basis points to 26.3%, with core margins up 90 basis points.

    • Diluted EPS increased 7% to $1.75, exceeding guidance of $1.67-$1.69.

    • Free cash flow was $394 million, achieving a strong 112% conversion rate to net income.

    • Overall orders grew 8% (organic up 3%), resulting in a book-to-bill of 1.04 and near-record backlog of $3.47 billion.

    • EMG sales grew 2% organically, with operating margins up 120 basis points to 21.9%, driven by strong Paragon Medical orders.

    Concerns

    3

    • Organic sales were down 1% company-wide, and EIG organic sales were down 2%.

    • Uncertainty around Q2 sales due to potential delays of approximately $70 million in direct U.S. to China shipments caused by 125% retaliatory tariffs.

    • Process business organic sales declined low single digits, with full-year organic sales now expected to be roughly flat due to project delays.

    Guidance & targets

    11
    CategoryTargetConfidence
    Full-year sales growth
    low single digits
    high materiality
    High
    Full-year diluted EPS
    $7.02 to $7.18
    high materiality
    High
    Full-year general and administrative expenses
    up modestly versus 2024 levels and to remain at approximately 1.5% of sales
    low materiality
    Medium
    Full-year effective tax rate
    between 19% and 20%
    medium materiality
    Medium
    Full-year capital expenditures
    approximately $155 million or about 2% of sales
    medium materiality
    Medium
    Full-year depreciation and amortization
    approximately $410 million
    low materiality
    Medium
    Full-year free cash flow conversion
    approximately 115% of net income
    high materiality
    High
    Process business organic sales growth
    roughly flat
    medium materiality
    Medium
    Aerospace and Defense organic sales growth
    mid-single digits
    medium materiality
    High
    Power business organic sales growth
    roughly flat
    medium materiality
    Medium
    Automation & Engineered Solutions organic sales growth
    mid-single-digit organic sales growth
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Electronic Instruments Group (EIG)
    Continued to deliver excellent operating performance, resulting in robust operating margins.
    Organic sales down 2%Acquisitions added 2 points to salesForeign currency was a 1 point headwind to salesOperating income $354.1 millionOperating margins up 50 basis pointsCore margins up 110 basis points
    		$1.14 billion-1%—31%
    Electromechanical Group (EMG)
    Delivered strong growth and excellent operating performance, with record sales.
    Organic sales up 2%Operating income $128.7 millionOperating income up 7% compared to prior yearOperating margins up 120 basis points from Q1 2024Experienced improving order patterns, especially within Paragon Medical business
    		$588.3 million2%—21.9%

    Operational metrics

    46
    Pretax charge for Paragon Medical integration
    $29.2 million
    Q1 2024

    Excluded from adjusted results for Q1 2024.

    EBITDA
    $559 millionup 3% versus prior year
    Q1 FY25

    Strong operating performance led to this EBITDA.

    EBITDA margin
    32.2%
    Q1 FY25

    Impressive EBITDA margin.

    Depreciation and amortization expense
    $106 million
    Q1 FY25

    Reported for the quarter.

    Total debt
    $1.9 billiondown from $2.1 billion at end of 2024
    March 31

    Total debt at the end of the first quarter.

    USMCA compliance
    over 98%
    current

    Very little exposure to tariffs due to high compliance with U.S. MCA guidelines.

    International sales
    high 40%
    Q1 FY25

    Sales through international markets, demonstrating global reach.

    Aerospace business as % of company
    17%-18%
    current

    Represents a stable, strong growing business for the company.

    Research exposure
    10%
    current

    Total research exposure as a percentage of sales, primarily international.

    Total sales
    $1.73 billionessentially in line with Q1 2024
    Q1 FY25

    Company-wide sales for the first quarter.

    Organic sales growth
    -1%YoY
    Q1 FY25

    Company-wide organic sales performance.

    Acquisition contribution to sales
    1 point
    Q1 FY25

    Contribution from acquisitions to overall sales growth.

    Foreign currency impact on sales
    flat
    Q1 FY25

    Impact of foreign currency fluctuations on sales.

    Operating income
    $455 million2% increase over Q1 2024
    Q1 FY25

    Company-wide operating income.

    Operating margin
    26.3%up 60 basis points from prior year
    Q1 FY25

    Company-wide operating margin.

    Core operating margin expansion
    90 bps
    Q1 FY25

    Excluding dilutive impact from acquisitions.

    Free cash flow to net income conversion
    112%
    Q1 FY25

    Strong conversion rate.

    Diluted EPS
    $1.75up 7% versus Q1 2024
    Q1 FY25

    Above guidance range of $1.67 to $1.69 per share.

    General and administrative expenses
    $28 millionup $1.5 million from prior year
    Q1 FY25

    Reported for the quarter.

    Other operating expenses
    up $1 millioncompared to Q1 2024
    Q1 FY25

    Due to lower interest and investment income.

    Interest expense
    $19 million
    Q1 FY25

    Reported for the quarter.

    Effective tax rate
    19%in line with Q1 2024
    Q1 FY25

    Reported for the quarter.

    Capital expenditures
    $23 million
    Q1 FY25

    Reported for the quarter.

    Operating working capital
    18.1%vs 18.7% in Q1 2024
    Q1 FY25

    Improved operating working capital.

    Cash and cash equivalents
    $399 million
    March 31

    Offsetting total debt.

    Gross debt-to-EBITDA ratio
    0.9x
    March 31

    Leverage ratio at quarter end.

    Net debt-to-EBITDA ratio
    0.7x
    March 31

    Leverage ratio at quarter end.

    Cash and available credit facilities
    $2.5 billion
    current

    Excellent financial capacity and flexibility to support growth initiatives and acquisitions.

    Quarterly cash dividend increase
    11% to $0.31 per share
    February

    Dividend increase announced in February.

    Share repurchase authorization
    $1.25 billion
    February

    Board approved authorization provides flexibility to enhance shareholder value.

    Vitality index
    26%
    Q1 FY25

    Measures sales of new products introduced in the past 3 years.

    Inflation
    a couple of points
    Q1 FY25

    Inflationary costs experienced in the quarter.

    Price realization
    positive spread
    Q1 FY25

    Covered all inflationary costs in Q1, expected to continue.

    China sales
    9%
    current

    Percentage of total sales in China, much of it local for local.

    Direct U.S. to China sales
    4%
    Q2 FY25

    Sales directly from U.S. to China, subject to retaliatory tariffs.

    Annual direct tariff impact
    $100 million
    annual

    Estimated direct impact from tariffs, expected to be offset by mitigation actions.

    Retaliatory tariffs on U.S. to China
    125%
    current

    Tariff rate imposed by China on U.S. imports.

    Tariffs on China imports to U.S.
    145%
    current

    Tariff rate on China imports to the U.S., limited exposure due to proactive sourcing shifts.

    Process business organic sales growth
    low single digits decline
    Q1 FY25

    Organic sales performance for the Process business.

    Aerospace and Defense organic sales growth
    mid-single digits
    Q1 FY25

    Organic sales performance for the Aerospace and Defense business, strongest in commercial OEM.

    Power business organic sales growth
    low single digits
    Q1 FY25

    Organic sales performance for the Power business, growth across power platform.

    Automation & Engineered Solutions organic sales growth
    low single digits decline
    Q1 FY25

    Organic sales performance for the Automation & Engineered Solutions business.

    OEM automation and MedTech OEM orders growth
    25%
    Q1 FY25

    Orders growth in these segments, with Paragon Medical leading.

    Paragon Medical profit margin
    25%
    Q1 FY25

    Profit margin for the Paragon Medical business.

    Number of U.S. plants
    100
    current

    Part of AMETEK's global manufacturing footprint.

    Number of international plants
    50
    current

    Part of AMETEK's global manufacturing footprint.

    Industry KPIs

    3
    MetricValueDetails
    Book to bill ratio1.04ratio
    Orders bookings growth8%%
    Backlog by segment end market$3.47 billionUSD

    Orderbook & backlog

    4
    Total backlog$3.47 billionend of Q1 FY25

    near record levels

    Some delays related to tariffs, particularly for products shipped directly to China. Backlog is not concentrated, with A&D and MedTech (Paragon) backlogs increasing.

    Overall orders growth8%Q1 FY25

    YoY

    Shows continued improvement for a third consecutive quarter. March was the strongest month, with solid performance continuing into April.

    Organic orders growth3%Q1 FY25

    YoY

    Part of the overall orders growth, indicating underlying demand strength.

    Book-to-bill ratio1.04Q1 FY25

    Indicates that new orders exceeded shipments in the quarter, contributing to backlog growth.

    Product announcements

    2
    ProductTypeDetails
    EDAX Elite Ultra Energy Dispersive X-ray Spectroscopy Systemlaunch
    Phantom KT series high-speed cameraslaunch

    Capital programs

    1
    Strategic Investments in Initiativesunderway
    Period spend: incremental $85 million

    Benefit: advance product differentiation, support global and market expansion, technology innovation

    Investment for all of 2025, with key investments in research, development, and engineering.

    Risks & headwinds

    6
    Trade policy uncertaintynear term

    Increased level of uncertainty

    Mitigation: Distributed operating structure, portfolio of differentiated products, broad market/geography exposure, global manufacturing footprint, strong balance sheet, tariff response plans (pricing, localization, supply chain adjustments, productivity actions).

    Direct annual tariff impactannual

    $100 million

    Mitigation: Expected to be offset through mitigation actions including select pricing initiatives, localization of production operations, adjustments to supply chain, and targeted productivity actions.

    Retaliatory tariffs on U.S. to China shipmentsQ2 FY25 (short-term delays)

    125% tariffs on approximately 4% of sales (about $70 million in Q2)

    Mitigation: Customers seeking exemptions for specialized products, initiating manufacturing and localization plans to change value-added nature of production, ability to sell products outside of China if delays persist.

    Project delays in Process businessFY25

    Organic sales declined low single digits in Q1; full-year organic sales expected to be roughly flat

    Mitigation: Adjusted annual outlook for the Process business; long-term project activity remains solid, but customers are cautious about placing POs.

    Modest international sales declinesQ1 FY25

    U.S. sales up, Europe and Asia sales down modestly; China market down about 10%

    Mitigation: Diversification across end markets and geographies limits dependence on any single region.

    OEM inventory destockingthroughout FY25

    Not yet completed for all customers, but showing signs of ending in some areas (e.g., U.S. automation, some MedTech OEMs)

    Mitigation: Customers recalibrating to demand levels; strong order growth in areas where destocking is ending (e.g., Paragon Medical).

    What to watch in Q2 FY25

    4

    Q2 Sales from U.S. to China

    Q2 FY25
    CurrentApproximately $70 million planned for Q2
    TargetConfirmation of shipment or clarity on delays

    Why it matters

    This represents 4% of total sales and is subject to 125% retaliatory tariffs, creating near-term uncertainty for Q2 results.

    We have the 125% retaliatory tariffs imposed by China on the U.S. And as you know🎣, we do about 9% of our sales in China, a lot of it is local for local, but we do have approximately 4% of our sales. So in the case of the second quarter, that will be about $70 million. They're direct U.S. to China.

    Q&A highlights

    5

    Seeking more detail on Paragon's order inflection and the overall medical segment's recovery after destocking.

    Paragon Medical saw orders "substantially greater than 25%" in Q1, leading the broader OEM automation and MedTech OEM businesses which were up 25%. This indicates customer destocking is ending. Paragon's profit margins were 25%, and the business is expected to drive substantial growth in H2 FY25 due to ongoing improvement plans and volume.

    “Paragon was greater than 25% -- substantially greater than 25%. So -- the customers are destocking. The business also performed very well on a profit margin basis. It was 25% in the quarter.”

    asked by Matt Summerville · answered by David Zapico

    2 min read7 chapters

    Detailed Narrative

    01

    First Quarter Performance Highlights

    AMETEK reported strong Q1 FY25 results, with sales of $1.73 billion, essentially flat year-over-year (organic sales down 1%, acquisitions up 1%). Operating income increased 2% to $455 million, leading to a 60 basis point expansion in operating margins to 26.3% (90 bps core margin expansion). Diluted EPS grew 7% to $1.75, exceeding guidance. Free cash flow was robust at $394 million, converting at 112% of net income.

    02

    Order Growth and Backlog Strength

    The company experienced strong order patterns, with overall orders up 8% and organic orders up 3% year-over-year. The book-to-bill ratio was 1.04, contributing to a near-record backlog of $3.47 billion at quarter-end. March saw the strongest order month, with solid performance continuing into April, indicating improving demand despite macro uncertainties.

    03

    Strategic Investments in Innovation

    AMETEK continues to invest significantly in research, development, and engineering, with an incremental $85 million planned for 2025 to support global expansion, market penetration, and technology innovation. The vitality index, measuring sales from new products introduced in the past three years, remained strong at 26% in Q1, highlighting successful product differentiation.

    04

    New Product Introductions

    Two notable new product introductions were highlighted: Gatan's EDAX Elite Ultra Energy Dispersive X-ray Spectroscopy System, which improves element mapping in advanced materials research, and Vision Research's Phantom KT series of high-speed cameras, leveraging custom sensors from Forza Silicon for advanced imaging applications. These demonstrate internal collaboration and commitment to innovation.

    05

    Capital Deployment Strategy

    Strategic acquisitions remain the top priority for capital deployment, with a robust pipeline of candidates. The company also maintains flexibility for opportunistic share repurchases, backed by a $1.25 billion authorization and strong free cash flow generation. A February dividend increase of 11% to $0.31 per share marked the sixth consecutive year of double-digit increases.

    06

    Navigation of Trade Conflicts and Tariffs

    AMETEK is actively addressing increased uncertainty from trade policies and tariffs. The company estimates a direct annual tariff impact🌐 of $100 million, which it expects to offset through mitigation actions including pricing, production localization, supply chain adjustments, and productivity. The company also noted a potential short-term Q2 sales delay of $70 million due to 125% retaliatory tariffs on U.S. to China shipments, though it expects to mitigate the full-year impact.

    07

    Segment Performance Overview

    EIG sales were down 1% (organic down 2%), but operating margins were strong at 31% (up 50 bps). EMG sales were up 2% (organic up 2%), with operating income up 7% and operating margins expanding 120 bps to 21.9%, driven by improving order patterns, particularly in Paragon Medical. Aerospace and Defense organic sales were up mid-single digits, while Process and Power organic sales were low single digits or flat.

    AI-generated summary of the company’s earnings call. Not investment advice.